CU20130084A7 - Determinación de la eficacia de una vacunación antimicobacteriana - Google Patents

Determinación de la eficacia de una vacunación antimicobacteriana

Info

Publication number
CU20130084A7
CU20130084A7 CU2013000084A CU20130084A CU20130084A7 CU 20130084 A7 CU20130084 A7 CU 20130084A7 CU 2013000084 A CU2013000084 A CU 2013000084A CU 20130084 A CU20130084 A CU 20130084A CU 20130084 A7 CU20130084 A7 CU 20130084A7
Authority
CU
Cuba
Prior art keywords
antimicobacterial
vaccination
effectiveness
determination
vaccine
Prior art date
Application number
CU2013000084A
Other languages
English (en)
Inventor
Christiane Desel
Stefan H E Kaufmann
Silke Bandermann
Leander Grode
Original Assignee
Vakzine Projekt Man Gmbh
Max Planck Ges Zur Förderungder Wissenschaften E V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Man Gmbh, Max Planck Ges Zur Förderungder Wissenschaften E V filed Critical Vakzine Projekt Man Gmbh
Publication of CU20130084A7 publication Critical patent/CU20130084A7/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se relaciona con métodos y reactivos para determinar la eficacia de una vacuna, en particular de una vacuna para la tuberculosis.
CU2013000084A 2010-12-21 2013-06-21 Determinación de la eficacia de una vacunación antimicobacteriana CU20130084A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425442P 2010-12-21 2010-12-21
PCT/EP2011/073609 WO2012085099A1 (en) 2010-12-21 2011-12-21 Determination of the efficacy of an anti-mycobacterial vaccination

Publications (1)

Publication Number Publication Date
CU20130084A7 true CU20130084A7 (es) 2013-12-27

Family

ID=45446021

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2013000084A CU20130084A7 (es) 2010-12-21 2013-06-21 Determinación de la eficacia de una vacunación antimicobacteriana

Country Status (25)

Country Link
US (1) US8906389B2 (es)
EP (1) EP2656070B9 (es)
JP (1) JP6055780B2 (es)
KR (1) KR101882040B1 (es)
CN (1) CN103492877B (es)
AU (1) AU2011347266B2 (es)
BR (1) BR112013015878B1 (es)
CA (1) CA2822715C (es)
CU (1) CU20130084A7 (es)
CY (1) CY1117412T1 (es)
DK (1) DK2656070T3 (es)
EA (1) EA029833B9 (es)
ES (1) ES2569035T3 (es)
HR (1) HRP20160558T1 (es)
HU (1) HUE027781T2 (es)
MX (1) MX345961B (es)
PH (1) PH12013501351A1 (es)
PL (1) PL2656070T3 (es)
PT (1) PT2656070E (es)
RS (1) RS54770B1 (es)
SG (1) SG191331A1 (es)
SI (1) SI2656070T1 (es)
SM (1) SMT201600149B (es)
UA (2) UA112067C2 (es)
WO (1) WO2012085099A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543698A1 (en) * 2018-03-20 2019-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH Method for determining vaccine efficacy in an individual and means therefore

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
ATE407206T1 (de) * 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
JP2001215224A (ja) * 1999-11-25 2001-08-10 Hitachi Chem Co Ltd 免疫反応のアッセイ法、免疫学的判定法及びアッセイキット
CA2523084C (en) 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy
EP2322553A3 (en) * 2005-02-14 2011-11-16 Wyeth LLC Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
CN101472611A (zh) * 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
CN101329230B (zh) * 2008-07-14 2010-10-20 中国人民解放军第三军医大学 改进的免疫荧光细胞染色方法
JP2010051307A (ja) * 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
WO2010046039A1 (en) * 2008-10-20 2010-04-29 University Of Zurich Mycobacterium tuberculosis vaccine
CN107126557A (zh) * 2009-06-29 2017-09-05 健诺西生物科学公司 抗肺炎链球菌的疫苗和组合物

Also Published As

Publication number Publication date
HUE027781T2 (en) 2016-11-28
CA2822715A1 (en) 2012-06-28
MX2013007244A (es) 2014-01-17
RS54770B1 (sr) 2016-10-31
DK2656070T3 (en) 2016-06-13
BR112013015878A2 (pt) 2016-10-04
SI2656070T1 (sl) 2016-05-31
EA029833B1 (ru) 2018-05-31
EP2656070B1 (en) 2016-03-09
UA112067C2 (uk) 2016-07-25
CA2822715C (en) 2019-04-30
CN103492877B (zh) 2015-04-01
CY1117412T1 (el) 2017-04-26
EP2656070A1 (en) 2013-10-30
EA029833B9 (ru) 2018-06-29
AU2011347266A1 (en) 2013-07-25
US8906389B2 (en) 2014-12-09
KR20140020243A (ko) 2014-02-18
HRP20160558T1 (hr) 2016-06-17
BR112013015878B1 (pt) 2020-10-27
US20130280739A1 (en) 2013-10-24
UA113282C2 (xx) 2017-01-10
ES2569035T3 (es) 2016-05-06
EA201300738A1 (ru) 2013-12-30
JP6055780B2 (ja) 2016-12-27
PT2656070E (pt) 2016-06-17
PH12013501351A1 (en) 2013-09-02
KR101882040B1 (ko) 2018-07-25
EP2656070B9 (en) 2017-01-04
SMT201600149B (it) 2016-07-01
JP2014502841A (ja) 2014-02-06
AU2011347266B2 (en) 2016-07-21
HK1192322A1 (en) 2014-08-15
CN103492877A (zh) 2014-01-01
SG191331A1 (en) 2013-07-31
WO2012085099A1 (en) 2012-06-28
MX345961B (es) 2017-02-28
PL2656070T3 (pl) 2017-01-31

Similar Documents

Publication Publication Date Title
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
BR112012004807A2 (pt) vacina para pcsk9
BR112015000530A2 (pt) vacina de antígeno micobacteriano.
IL238958B (en) Glutaminase inhibitors, compositions comprising same and uses thereof
IL248607A (en) Methods and compositions for immunization against virus
DK2528621T3 (da) Modificerede tuberkuloseantigener
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CO6781493A2 (es) Inhibidores de la faah
BR112013014605A2 (pt) sistemas e métodos para aspiração de calibre pequeno
BR112013012854A2 (pt) métodos de tratamento usando os inibidores de bcl-2 seletivos
BR112012031232A2 (pt) método, dispositivo e uso
BR112014001962A2 (pt) dispositivo, sistema e método para restauração prostodôntica
PL2882440T3 (pl) Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa
ITRM20120383A1 (it) Metodo e kit per la rivelazione di anticorpi.
IL222930B (en) Chlorotoxin variants, conjugates and methods for their use
FI20105534A0 (fi) Katkaisu- ja pilkkomislaite
PT2758655T (pt) Sistemas e métodos para rotores hidráulicos melhorados
BR112013015942A2 (pt) dispositivos de bomba e métodos para utilizar os mesmos.
EP2721520A4 (en) SELECTION DISPLAY BETWEEN RECEIVED FILES AND SOURCE FILES
SMT201600082B (it) Vaccino pcsk9
FI20115904L (fi) Iskuvasaran työkalu, iskuvasara ja sen käyttö
EP2849830A4 (en) HEAD COVER, INTERFACE AND ARRANGEMENT
EP2697246A4 (en) SELECTIVE CYSTONE PROTEASE INHIBITORS AND USES THEREOF
BR112013012175A2 (pt) combinação, coadministração, uso e método